EICHORPublic-registry site landscape for NCT03149575, “VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM”, a Glioblastoma Multiforme study sponsored by DelMar Pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03149575 (registry record) |
| Study title | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM |
| Official title | A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3) |
| Sponsor | DelMar Pharmaceuticals, Inc. |
| Condition(s) | Glioblastoma Multiforme; Glioblastoma; Glioma; GBM |
| Phase | PHASE3 |
| Listed sites | 5 |
| Intervention(s) | VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine, Physician's Choice of Salvage Therapy - carboplatin |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03149575.
Eichor generates a preliminary site-risk snapshot for NCT03149575 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
